0001855763-24-000001.txt : 20240216 0001855763-24-000001.hdr.sgml : 20240216 20240216154726 ACCESSION NUMBER: 0001855763-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 EFFECTIVENESS DATE: 20240216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lexaria Bioscience Corp. CENTRAL INDEX KEY: 0001348362 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 202000871 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-505502 FILM NUMBER: 24648024 BUSINESS ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 BUSINESS PHONE: 250-765-6424 MAIL ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 FORMER COMPANY: FORMER CONFORMED NAME: LEXARIA CORP. DATE OF NAME CHANGE: 20080229 FORMER COMPANY: FORMER CONFORMED NAME: Lexaria Corp. DATE OF NAME CHANGE: 20051229 D 1 primary_doc.xml X0708 D LIVE 0001348362 Lexaria Bioscience Corp. 100 - 740 MCCURDY ROAD KELOWNA A1 BRITISH COLUMBIA, CANADA V1X 2P7 250-765-6424 NEVADA LEXARIA CORP. Lexaria Corp. Corporation true Christopher Bunka 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Executive Officer Director John Docherty 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Executive Officer Director Nicholas Baxter 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director TED MCKECHNIE 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1Y 2P7 Director ALBERT REESE 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director CATHERINE TURKEL 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director Pharmaceuticals $1 - $1,000,000 06b false 2024-02-16 false true false 0 H.C. WAINWRIGHT & CO. 375 None None 430 Park Avenue 4th Floor New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK false 3600003 3600003 0 false 2 222000 0 0 false Lexaria Bioscience Corp. /s/ Christopher Bunka Christopher Bunka CEO 2024-02-16